Of note, with these studies, it became clear that CD79 and MYD88 mutations were mutually exclusive with other known recurrent alterations occurring in DLBCLs, such as translocations of MYC and BCL2 and/or BCL6, as observed in the new WHO category of high-grade B-cell lymphomas. This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.